| Identification | Back Directory | [Name]
2-[(2-fluorobenzoyl)amino]-N-[2-(4-morpholinyl)ethyl]benzamide | [CAS]
950244-33-4 | [Synonyms]
JS6
2-[(2-fluorobenzoyl)amino]-N-[2-(4-morpholinyl)ethyl]benzamide | [Molecular Formula]
C20H22FN3O3 | [MOL File]
950244-33-4.mol | [Molecular Weight]
371.405 |
| Hazard Information | Back Directory | [Uses]
JS6 is a Bcl3 inhibitor, and inhibits Bcl3-NF-kB1 binding. JS6 inhibits tumor cell growth in vitro and in vivo[1]. | [Biological Activity]
JS6 is a Bcl3:NF-kB p50 protein-protein interaction (PPI) inhibitor th at effectively suppresses Bcl3-dependent intracellular NF-kB activity (IC50 = 45/159 nM using Bcl3-overexpressing MDA-MB-231/HEK293; IC50 = 710 nM using HEK293 overexpressing Bcl3 and NF-kB p52). JS6 prevents enhanced MDA-MB-231 migration upon Bcl3 overexpression in cultures (IC50 = 310 nM)and effectively suppresses primary tumor growth as well as secondary tumor colonisation in vivo (3.5-10 mg/kg/d i.p. mice with MDA-MB-436 or 4T1.2 murine carcinoma xenograft) without overt systemic toxicity. | [References]
[1] Soukupová J, et al. The Discovery of a Novel Antimetastatic Bcl3 Inhibitor. Mol Cancer Ther. 2021;20(5):775-786. DOI:10.1158/1535-7163.MCT-20-0283 |
|
| Company Name: |
Merck KGaA
|
| Tel: |
21-20338288 |
| Website: |
www.sigmaaldrich.cn |
| Company Name: |
Specs
|
| Tel: |
+31 15 251 8111 |
| Website: |
www.specs.net |
|